相关实验视频

Updated: Jan 10, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

绝经后妇女的激素替代疗法和血清尿酸:心脏代谢洞察力

Anna Vittoria Mattioli¹, Camilla Cocchi², Valentina Selleri³

¹Department of Quality of Life Sciences, Alma Mater Studiorum University, Bologna, Italy.

Nutrition, metabolism, and cardiovascular diseases : NMCD

|November 26, 2025

概括

激素替代疗法 (HRT) 的使用与血清尿酸 (SUA) 的降低和更好的心脏代谢健康在绝经后的妇女. 这表明HRT可能为心血管预防提供保护性代谢作用.

科学领域:

心血管医学心血管医学
内分泌学在内分泌学.
代谢健康代谢健康

背景情况:

血清尿酸 (SUA) 升高是绝经后妇女心脏代谢风险的重要标志物.
激素替代疗法 (HRT) 对SUA水平的影响及其临床影响需要进一步研究.

研究的目的:

为了比较使用HRT和不使用HRT的绝经后妇女之间的血清尿酸 (SUA) 水平和心脏代谢指标.
探索HRT在调节SUA和心脏代谢风险因素方面的潜在作用.

主要方法:

在心血管预防队列中,对440名绝经后妇女进行了横截面分析.
参与者被分为HRT使用者 (n=109) 和非使用者 (n=331).
收集了临床,生化和生活方式数据,并使用t测试比较了SUA和脂质资料.

主要成果:

与非使用者相比,HRT使用者表现出明显较低的SUA水平 (5.4 ± 0.27 mg/dL) (6.6 ± 0.24 mg/dL,p < 0.001).
HRT使用者还显示LDL胆固醇,体重指数 (BMI) 和腰围都降低了.
两组之间没有观察到功能显著差异.

结论:

激素替代疗法 (HRT) 的使用与血清尿酸 (SUA) 的降低和更有利的心脏代谢特征有关.
HRT可能具有保护性代谢作用,可能有助于量身定制的心脏代谢风险降低策略.

关键词:

心脏代谢健康的健康状况激素替代疗法是一种激素替代疗法.脂质脂质脂质是一种更年期绝经绝经血清尿酸中的尿酸.女人女人女人女人女人

更多相关视频

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...